参考文献/References:
[1] LUO E,WANG D,YAN G,et al.High triglyceride-glucose index is associated with poor prognosis in patients with acute st-elevation myocardial infarction after percutaneous coronary intervention[J].Cardiovasc Diabetol,2019,18(1):150-158.
[2] 田野,何亚军.急性心肌梗死经皮冠状动脉介入治疗患者血清同型半胱氨酸水平预测不良心血管事件的价值及其相关性分析[J].陕西医学杂志,2022,51(10):1223-1226,1239.
[3] 董欣欣,钱丽霞.FT-CMRI技术评估ST抬高型急性心肌梗死PCI术后微循环障碍的临床价值[J].中国CT和MRI杂志,2023,21(8):60-63.
[4] 裴思雨,苗浩,刘鑫,等.MR心肌应变对急性ST段抬高型心肌梗死患者急诊PCI术后近期发生主要心血管不良事件的预测价值[J].中华放射学杂志,2023,57(8):897-903.
[5] YANG Y,HUANG Y.Association between serum hemoglobin and major cardiovascular adverse event in chinese patients with st-segment elevation myocardial infarction after percutaneous coronary intervention[J].J Clin Lab Anal,2022,36(1):24126-24129.
[6] 张洁,王晓红,杨华,等.急性心肌梗死部位及NT-pro BNP水平与STEMI患者行PCI后CI-AKI发生率的关系及意义研究[J].临床和实验医学杂志,2022,21(12):1254-1258.
[7] 高峰,罗志丹,黄薇,等.血清胱抑素C及尿酸对急性ST段心肌梗死的诊断价值分析[J].川北医学院学报,2020,35(1):78-81.
[8] 方文忠.急性ST段抬高性心肌梗死早期血小板淋巴细胞比值与不良心血管事件的相关性分析[J].中西医结合心脑血管病杂志,2018,16(6):742-744.
[9] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
[10] 胡大一,马长生.心血管内科学[M].2 版.北京:人民卫生出版社,2014:120-123.
[11] NAHLER M P G.New York heart association classification(nyha)[M].Vienna:Springer Verlag,2009:143-144.
[12] 蒋守涛,吴永刚,叶少强,等.通阳宽胸方联合PCI治疗急性心肌梗死疗效及对患者血管内皮功能的影响[J].陕西中医,2020,41(7):871-874.
[13] SANTOSO A,YULIANTO Y,SIMARMATA H,et al.Effect of pcsk9 e670g and r46l polymorphisms on major adverse cardio-cerebrovascular events in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Int J Angiol,2021,30(1):22-28.
[14] 林佑妮,陈协辉.绕行急诊科及CCU对急性ST抬高型心肌梗死行PCI患者再灌注时间及预后的影响[J].罕少疾病杂志,2022,29(10):33-34.
[15] 王益,耿海华,刘廷.老年急性ST段抬高型心肌梗死患者院内发生主要心血管不良事件的危险因素及风险模型构建[J].中国老年学杂志,2022,42(20):4921-4924.
[16] ZHAO H,SHENG Z,TAN Y,et al.High human antimicrobial peptide ll-37 level predicts lower major adverse cardiovascular events after an acute st-segment elevation myocardial infarction[J].J Atheroscler Thromb,2022,29(10):1499-1510.
[17] 陈鑫森,邵萌,张天,等.血液学参数预测急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后发生主要不良心血管事件的价值研究[J].中国全科医学,2020,23(27):3389-3395.
[18] 张静,敖家富,方红义,等.急性ST段抬高型心肌梗死患者院内主要心血管不良事件的危险因素分析[J].安徽医学,2023,44(7):813-818.
[19] LIU Y H,DAI Y N,WANG L T,et al.Association between dbp and major adverse cardiovascular events in patients with st-segment elevation myocardial infarction undergoing percutaneous coronary intervention[J].J Hypertens,2022,40(4):692-698.
[20] 吴超,赵雪燕,袁晋青,等.NT-proANP、NT-proBNP和NT-proCNP对心力衰竭患者心源性事件预后预测价值的比较[J].中国分子心脏病学杂志,2021,21(3):3949-3952.
[21] 周奕,薛青,李玥.HEART评分联合NT-proBNP对非ST段抬高型急性冠脉综合征患者心血管不良事件的预测价值[J].中华急诊医学杂志,2022,31(3):374-378.
[22] 孙莹莹,常丽辉,苗文霞.老年急性ST段抬高型心肌梗死患者血清RF、CysC水平与直接PCI术后无复流的关系[J].现代检验医学杂志,2022,37(2):184-189.
[23] 刘瑞霞,范晓英.血小板-淋巴细胞比值预测急性ST段抬高型心肌梗死患者直接PCI术后心血管不良事件的价值[J].中华保健医学杂志,2020,22(5):506-508.
[24] WANG Y,PENG Z.Prognostic value of platelet/lymphocyte ratio and cami-stemi score for major adverse cardiac events in patients with acute st segment elevation myocardial infarction after percutaneous coronary intervention:A prospective observational study[J].Medicine(Baltimore),2021,100(33):26942-26945.
相似文献/References:
[1]夏旭东,贾凯侠△.首次急性ST段抬高型心肌梗死行经皮冠状动脉介入术后心动过缓发生情况及危险因素分析[J].陕西医学杂志,2020,49(10):1303.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.027]
[2]张 玲,郭利军△.氢氯吡格雷与替格瑞洛在急性ST段抬高型心肌梗死合并2型糖尿病患者经皮冠状动脉介入治疗中的效果观察[J].陕西医学杂志,2020,49(10):1339.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.037]
ZHANG Ling,GUO Lijun..Efficacy of hydroclopidogrel and ticagrelor in PCI in patients with acute ST-segment elevation myocardial infarction and type 2 diabetes mellitus[J].,2020,49(4):1339.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.037]
[3]李卫国,韩 晶,陶 凌,等.血流储备临界值时单纯左前降支中度狭窄患者治疗方案临床研究[J].陕西医学杂志,2021,50(4):450.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.017]
LI Weiguo,HAN Jing,TAO Ling,et al.The choice of treatment scheme of critical value of blood flow reserve in patients with moderate stenosis of left anterior descending artery[J].,2021,50(4):450.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.017]
[4]车奕宏,吕 晶,任琳子.急性冠状动脉综合征患者糖化血红蛋白水平与其严重程度关系及对介入术预后评估价值[J].陕西医学杂志,2022,51(1):44.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.011]
[5]梅丽军,王西强,崔倩卫,等.主动脉内球囊反搏在复杂高危有指征患者病变介入治疗中的临床应用研究[J].陕西医学杂志,2024,(2):231.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.018]
MEI Lijun,WANG Xiqiang,CUI Qianwei,et al.Clinical study of intra-aortic balloon pump in interventional treatment of CHIP lesions[J].,2024,(4):231.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.018]
[6]刘丁铭,程亚玲,杨红祥,等.利伐沙班与华法林在心房颤动患者经皮冠状动脉介入治疗术后临床应用效果对比研究[J].陕西医学杂志,2024,(3):395.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.023]
LIU Dingming,CHENG Yaling,YANG Hongxiang,et al.Comparative study of clinical efficacy of rivaroxaban and warfarin in patients with atrial fibrillation after percutaneous coronary intervention[J].,2024,(4):395.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.023]